225Research

225Research strives to find strong investment opportunities and aims to provide in-depth and insightful analysis of these opportunities for our readers.

Month: September 2018

Akumin: The Acquisition Screener

4 acquisitions and deals in 4 months, Akumin has been making some moves. But are they worth buying? Akumin is a TSX listed company specializing in diagnosing imaging centers located in the us. After their latest acquisition, they now have…

Jack Ma and the future of Alibaba

Jack Ma, the founder of Alibaba, has announced that he will be leaving the company entirely, as of 2019. But what we want to know, is if it’s finally time to buy the dip?   Alibaba is the largest Chinese…

FSD Pharma: HUGE downside potential coming…

When it comes to a company like FSD Pharma, with a large run as of late, it’s important to really understand what your buying. We had it in December with LGC Capital shooting up to a crazy $1 per share,…

Tilray- the Rocket that Won’t Stop, or Will it?

Tilray’s gains are too insane not to write about, and today we watched it gain in an hour mid-day, a crazy $12 a share. I should have listened to my dad telling me at $32 to buy this, but as…

SNC Lavalin- the Trading Range of the Decade… Literally

SNC Lavalin is a multinational engineering and construction company listed under the symbol SNC on the TSX. We see this stock with long term hold potential, as well as an ideal swing trade where its trading right now. Swing Trade…